#83 - Bill Harris, Ph.D.: Omega-3 fatty acids

Episode Summary

Executive Summary: Peter Attia opens by explaining the podcast’s no-ads, subscriber-supported model to preserve trust and independence, then interviews omega-3 expert Dr. Bill Harris. The conversation covers fatty-acid chemistry, omega-3/omega-6 pathways, the history of fish-oil research, clinical effects on lipids and cardiovascular risk, the REDUCE-IT and VITAL trials, and why measuring the omega-3 index may be clinically useful.

Main Topics: Podcast funding and trust model (Priority: 5/5): Attia explains why the show avoids ads and instead uses subscriptions, arguing that direct support preserves honesty, trust, and editorial independence while funding high-quality show notes and member benefits. Fatty-acid chemistry and nomenclature (Priority: 5/5): Harris breaks down saturated, monounsaturated, and polyunsaturated fats, including omega-3 and omega-6 families, and explains how chain length, double bonds, and omega position determine structure and function. Origins of omega-3 research (Priority: 5/5): Harris recounts his 1980 salmon-oil study showing triglyceride lowering and modest cholesterol reduction, which helped launch decades of omega-3 research and clarified that fish oil’s effects were distinct from plant oils. EPA, DHA, and clinical effects (Priority: 5/5): The discussion details how ALA converts poorly to EPA/DHA, how EPA and DHA affect membranes, platelets, inflammation, and triglycerides, and why EPA-only and EPA+DHA products may differ in lipid effects. Cardiovascular outcomes evidence (Priority: 5/5): They review REDUCE-IT, VITAL, and earlier studies, emphasizing that high-dose EPA reduced cardiovascular events in high-risk patients, while lower-dose primary-prevention data were more mixed but still suggested benefit in some endpoints. Omega-6, arachidonic acid, and ratio debates (Priority: 4/5): Harris argues that linoleic acid is not inherently harmful, that arachidonic acid is tightly regulated and not strongly driven by diet, and that simplistic omega-6:omega-3 ratios can obscure the real issue: low EPA/DHA status. Testing omega-3 status in practice (Priority: 4/5): The conversation ends with practical guidance on measuring the omega-3 index, target ranges, tissue correlations, and the value of monitoring blood levels to guide diet or supplementation.

Key Arguments: Trust is central to the podcast’s funding model; ads would create a conflict between sponsorship and honest recommendation. Fatty-acid structure matters: saturation level and double-bond position strongly influence physical properties and biological effects. Fish oil lowered triglycerides in early studies, establishing omega-3s as clinically relevant beyond cholesterol lowering. EPA and DHA are not interchangeable; EPA appears especially important for anti-inflammatory and antiplatelet effects, while DHA may be stronger for triglyceride lowering and can raise LDL in some settings. High-dose EPA reduced cardiovascular events in REDUCE-IT even with only modest triglyceride lowering, suggesting mechanisms beyond lipid reduction. The benefit of omega-3s is not limited to eating fish; supplements can reproduce many effects, though fish remains a good source when feasible. Omega-6 linoleic acid is not clearly harmful in epidemiologic data; higher blood linoleic acid has been associated with lower heart disease and diabetes risk. Arachidonic acid has been unfairly demonized; it is a regulated precursor for both pro- and anti-inflammatory mediators. The omega-3 index is a more useful clinical metric than omega-6:omega-3 ratios because it directly reflects EPA+DHA status. Red blood cell omega-3 levels correlate with several tissues and are a practical long-term biomarker, though not perfect for every organ. ALA from flax/chia/soy is not an effective substitute for EPA/DHA because conversion is minimal. Supplement quality is generally acceptable when sourced from reputable manufacturers, but dose, formulation, and whether the product is ethyl ester or free fatty acid matter for absorption.

Data Points: Salmon oil dose in first study: ~25 g/day EPA+DHA - Harris’s 1980 metabolic ward study fed subjects salmon oil and salmon steaks to test lipid effects. Cholesterol change in first study: ~250 to ~230 mg/dL - Approximate total cholesterol reduction seen with salmon oil relative to saturated fat diet. Triglyceride change in first study: ~100 to ~75 mg/dL - Early evidence that omega-3s lowered triglycerides, unlike prior fat studies. Average EPA+DHA intake in modern diet: ~100–150 mg/day - Harris estimates typical American intake of combined EPA and DHA is very low. Okinawan intake: ~1.5–2 g/day EPA+DHA - Historical estimate for a seafood-rich population. Eskimo intake: ~6–7 g/day EPA+DHA - Dyerberg and Bang’s Greenland studies documented very high omega-3 intake. High-dose triglyceride treatment: ~18–20 g/day EPA+DHA - Used in later studies of severe hypertriglyceridemia, producing dramatic triglyceride reductions. Severe triglyceride reduction example: ~2000 to ~250 mg/dL - Illustrative effect of high-dose fish oil in patients with very high triglycerides. REDUCE-IT dose: 4 g/day EPA (icosapent ethyl) - EPA-only prescription product tested in high-risk statin-treated patients. REDUCE-IT outcome: 25% reduction in cardiovascular events - Major outcome benefit over roughly 4–5 years in patients with elevated triglycerides. REDUCE-IT triglyceride effect: ~15% reduction - Benefit occurred despite only modest triglyceride lowering. REDUCE-IT LDL effect: Minimal/none - Attia and Harris note little LDL-C change in the EPA-only trial. VITAL dose: 1 Lovaza capsule (~850 mg EPA+DHA) - Primary-prevention trial in generally healthy adults. VITAL finding: No significant effect on primary composite endpoint - But some components, such as MI, appeared reduced. Omega-3 index target: 8%–12% - Harris’s preferred red-blood-cell EPA+DHA target range. Average omega-3 index in Americans: ~4%–5% - Typical baseline level in the U.S. population. High RBC omega-3 example: ~16% EPA+DHA - Observed in a person taking omega-3 by the truckload. Linoleic acid intake: ~15 g/day - Approximate average intake of omega-6 linoleic acid in the diet. Arachidonic acid intake: ~0.1 g/day - Average daily intake is much lower than linoleic acid. LA to AA conversion: <1% - Dietary linoleic acid is only minimally converted to arachidonic acid. ALA to EPA conversion: Very low; 12 g ALA only modestly raises EPA - Harris says even large ALA doses barely move EPA levels. Fish oil test price: $50 - Direct-to-consumer omega-3 index test from OmegaQuant. Time to reach new steady state: ~4 months - How long after changing intake before RBC omega-3 levels stabilize. Mercury concern fish: Tilefish, swordfish, king mackerel, shark - Species highlighted as higher-mercury choices to avoid, especially in pregnancy.

Pivotal Quotes: "“I have a really hard time advocating for something that I'm not absolutely nuts for.”" — Peter Attia: Explaining why he avoids ads and prefers a subscriber model to preserve trust. "“The thing that was unique about salmon oil was that it lowered triglyceride levels.”" — Bill Harris: Describing the key finding from his first omega-3 study in 1980. "“The problem is the lack of EPA and DHA.”" — Bill Harris: Summarizing his view that omega-3 deficiency, not omega-6 excess, is the main actionable issue.

Implications: Listeners should focus less on simplistic fat fear and more on getting adequate EPA/DHA, ideally guided by an omega-3 index. For clinicians and industry, formulation, dose, and biomarker monitoring matter more than broad “fish oil” labels.